Inovio Pharmaceuticals (NASDAQ:INO) “Buy” Rating Kept Today By H.C. Wainwright; The Target Price is $13.0

September 17, 2017 - By Kurt Siggers

 Inovio Pharmaceuticals (NASDAQ:INO)

Inovio Pharmaceuticals (NASDAQ:INO) Rating Reaffirmed

The broker has just set a price target of $13.0 on Inovio Pharmaceuticals (NASDAQ:INO) shares. This is 117.76 % from the last price. In a note released on Tuesday morning, H.C. Wainwright reconfirmed their “Buy” rating on shares of INO.

Inovio Pharmaceuticals Inc (NASDAQ:INO) Ratings Coverage

Among 7 analysts covering Inovio Pharmaceuticals (NASDAQ:INO), 7 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Inovio Pharmaceuticals has $31 highest and $9 lowest target. $14.75’s average target is 147.07% above currents $5.97 stock price. Inovio Pharmaceuticals had 25 analyst reports since August 10, 2015 according to SRatingsIntel. As per Tuesday, August 8, the company rating was maintained by Stifel Nicolaus. The rating was maintained by Maxim Group on Thursday, June 8 with “Buy”. Stifel Nicolaus maintained the stock with “Buy” rating in Monday, June 26 report. The company was upgraded on Thursday, June 8 by PiperJaffray. On Thursday, May 25 the stock rating was maintained by H.C. Wainwright with “Buy”. As per Thursday, June 8, the company rating was maintained by H.C. Wainwright. PiperJaffray downgraded Inovio Pharmaceuticals Inc (NASDAQ:INO) on Thursday, March 16 to “Neutral” rating. Maxim Group maintained it with “Buy” rating and $23 target in Wednesday, September 9 report. The firm has “Hold” rating by Maxim Group given on Tuesday, August 9. Maxim Group maintained it with “Buy” rating and $14.0 target in Tuesday, January 5 report.

The stock increased 0.84% or $0.05 on September 15, reaching $5.97. About 4.35 million shares traded or 259.50% up from the average. Inovio Pharmaceuticals Inc (NASDAQ:INO) has declined 29.01% since September 17, 2016 and is downtrending. It has underperformed by 45.71% the S&P500.

Analysts await Inovio Pharmaceuticals Inc (NASDAQ:INO) to report earnings on November, 8. They expect $-0.19 EPS, up 32.14 % or $0.09 from last year’s $-0.28 per share. After $-0.13 actual EPS reported by Inovio Pharmaceuticals Inc for the previous quarter, Wall Street now forecasts 46.15 % negative EPS growth.

Inovio Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The company has market cap of $538.66 million. The Company’s DNA immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases. It currently has negative earnings. It has completed, current or planned clinical programs of its SynCon immunotherapies for human papillomavirus (HPV)-caused pre-cancers and cancers, influenza, prostate cancer, breast/lung/pancreatic cancer, hepatitis C virus (HCV), hepatitis B virus (HBV), human immunodeficiency virus (HIV), Ebola, Middle East Respiratory Syndrome (MERS) and Zika virus.

More important recent Inovio Pharmaceuticals Inc (NASDAQ:INO) news were published by: Fool.com which released: “Better Buy: Inovio Pharmaceuticals, Inc. vs. Novavax, Inc.” on August 25, 2017, also Zacks.com published article titled: “Surging Earnings Estimates Signal Good News for Inovio (INO) September 07, 2017”, Globenewswire.com published: “Inovio Pharmaceuticals to Participate in Upcoming Investment Conferences” on August 23, 2017. More interesting news about Inovio Pharmaceuticals Inc (NASDAQ:INO) was released by: Fool.com and their article: “Is Inovio Pharmaceuticals Stock Poised for a Rebound?” with publication date: August 29, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.